Search results for "embolism"

showing 10 items of 457 documents

Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA).

2014

SummaryAcute pulmonary embolism (PE) is a serious complication in association with malignant diseases. We describe the successful treatment of PE applying a systemic thrombolytic therapy in a 4-year-old boy with acute lymphoblastic leukaemia.The thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) 0.1 mg/ kg bodyweight per hour for six hours was continued for six days without important side effects. In particular no bleeding complications were observed. Computed tomography with contrast revealed a remarkable regression of the central PE. Without further delays the chemotherapy was resumed.

Malemedicine.medical_specialtyLeukemia T-Cellmedicine.medical_treatmentComputed tomographyFibrinolytic AgentsmedicineHumansRecombinant tissue plasminogen activatorChemotherapymedicine.diagnostic_testbusiness.industryAnticoagulantsHematologyHeparin Low-Molecular-Weightmedicine.diseaseRecombinant ProteinsSurgeryPulmonary embolismTreatment OutcomeChild PreschoolTissue Plasminogen ActivatorLymphoblastic leukaemiaDrug Therapy CombinationbusinessComplicationPulmonary EmbolismT cell leukaemiaHamostaseologie
researchProduct

Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work.

2018

Objectives\ud Pulmonary embolism (PE) is associated with a substantial economic burden. However evidence from patients in Europe is scarce. The aim of this study was to report the impacts of PE on healthcare resource utilization (HCRU) and return to work using the PREFER in VTE registry.\ud \ud Methods\ud The PREFER in VTE registry was a prospective, observational, multicenter study in seven European countries, aiming to provide data concerning treatment patterns, HCRU, mortality, quality of life and work-loss. Patients with a first-time or recurrent PE were included and followed up at 1, 3, 6 and 12 months. Treatment patterns, re-hospitalization rates, length of hospital stays (LOS), and a…

Malemedicine.medical_specialtyMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineReturn to WorkQuality of lifeInternal medicineHealth careMedicineHumans030212 general & internal medicinebusiness.industryProportional hazards modelCancerHematologymedicine.diseasePulmonary embolismEuropeAmbulatoryQuality of LifeObservational studyFemalebusinessPulmonary EmbolismThrombosis research
researchProduct

Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area.

2001

Abstract Background. Thromboembolism has been reported to be associated with inflammatory bowel disease. Aim. To evaluate the association of factor V Leiden and prothrombin gene mutation with inflammatory bowel disease in a population of patients with thromboembolic events and inflammatory bowel disease and in a control population of patients with inflammatory bowel disease without thromboembolic events. Patients and methods. A series of 18 patients with inflammatory bowel disease and a history of arterial or venous thrombosis and 45 patients with inflammatory bowel disease without thromboembolic events were evaluated for the presence of factor V Leiden and prothrombin gene mutation. Freque…

Malemedicine.medical_specialtyPathologyProthrombin gene mutationPopulationGene mutationGastroenterologyInflammatory bowel diseaseCrohn Diseasehemic and lymphatic diseasesInternal medicineThromboembolismFactor V LeidenmedicinePrevalenceHumansPoint Mutationeducationeducation.field_of_studyHepatologybusiness.industryMediterranean RegionGastroenterologyFactor VMiddle Agedmedicine.diseaseVenous thrombosisMediterranean areaColitis UlcerativeFemaleProthrombinFactor V Leiden mutationbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Role of Associated Cortical Lesions in Motor Partial Seizures and Lenticulostriate Infarcts

1995

In a population-based study, we evaluated seizures occurring in the first 15 days after strokes among 1,640 consecutive patients who had ischemic (814 infarcts with atheroma and 126 with cardiogenic embolism, 273 lacunar infarcts, 259 transient ischemic attacks) or hemorrhagic stroke (129 supratentorial hematomas and 24 subarachnoïd hemorrhage) on computed tomography (CT) scan. Ninety patients had an epileptic seizure in the first 15 days after stroke onset. Thirteen of the 90 had a lenticulostriate infarct, diagnosed on CT scan, without an apparent ipsilateral cortical ischemic lesion. No lenticulostriate hematoma was observed with seizures. To determine the possible existence of an ipsila…

Malemedicine.medical_specialtyPathologySubarachnoid hemorrhagePopulationFunctional LateralityCentral nervous system diseaseEpilepsyHematomamedicineHumanscardiovascular diseaseseducationStrokeAgedTomography Emission-Computed Single-Photoneducation.field_of_studymedicine.diagnostic_testbusiness.industryElectroencephalographyMagnetic resonance imagingCerebral InfarctionIntracranial Embolism and Thrombosismedicine.diseaseMagnetic Resonance ImagingCerebrovascular DisordersNeurologyIschemic Attack TransientFemaleEpilepsies PartialNeurology (clinical)RadiologyEpileptic seizuremedicine.symptomTomography X-Ray ComputedbusinessEpilepsia
researchProduct

Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2) : a multinational, multicentre, single-ar…

2021

BACKGROUND: Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duration of hospitalisation) is currently unknown. We investigated whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran), is effective and safe. METHODS: We did a multinational, multicentre, single-arm, phase 4 trial at 42 hospitals in Austria, Belgium, France, Germany, Italy, Netherlands, Romania, Slovenia, and Spain. …

Malemedicine.medical_specialtyPopulationAdministration OralHemorrhage030204 cardiovascular system & hematologyDrug Administration ScheduleDabigatran03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumans030212 general & internal medicineeducationAgedAged 80 and overeducation.field_of_studyRIGHT-VENTRICULAR DYSFUNCTION VENOUS THROMBOEMBOLISM DABIGATRAN MANAGEMENT WARFARIN HOSPITALIZATION RATIONALE HEPARIN DESIGNHeparinbusiness.industryAnticoagulantsVenous ThromboembolismHematologyGuidelineHeparinMiddle AgedInterim analysismedicine.diseaseThrombosisDabigatran3. Good healthPulmonary embolismClinical trialTreatment OutcomeFemalePulmonary EmbolismbusinessFollow-Up Studiesmedicine.drug
researchProduct

Efficacy of delayed thromboprophylaxis with dabigatran: Pooled analysis

2012

Abstract Introduction Oral thromboprophylaxis with dabigatran etexilate should be initiated as a half dose 1 to 4 h after major orthopaedic surgery. However, a delay in dosing could occur for clinical or logistical reasons. A post hoc analysis was carried out to determine if patients with delayed dosing received adequate anticoagulation. Patients and methods The RE-MODEL™ and RE-NOVATE® trials compared 220 mg and 150 mg dabigatran etexilate with 40 mg enoxaparin. Pooled data for major venous thromboembolism (VTE) and VTE-related mortality (efficacy outcome) and major bleeding events (MBE), MBE/clinically relevant bleeding events, and all bleeding events (safety outcomes) were analysed. Resu…

Malemedicine.medical_specialtyPyridinesAntithrombinsDrug Administration ScheduleDabigatranlaw.inventionDouble-Blind MethodRandomized controlled triallawPost-hoc analysisHumansMedicineOrthopedic ProceduresProspective StudiesDosingEnoxaparinProspective cohort studyAgedbusiness.industryAnticoagulantsVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseDabigatranPulmonary embolismTreatment OutcomeAnesthesiaOrthopedic surgeryBenzimidazolesFemalebusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct

Radiographic and chest CT imaging presentation and follow-up of COVID-19 pneumonia: a multicenter experience from an endemic area.

2020

COVID-19 has infected more than 2 million people in the world in less than 5 months outbreak. Chest imaging is recommended for triage of suspected cases of COVID-19 with moderate-severe clinical features and high pre-test probability of disease, and may help for patient follow-up and to identify patients at higher risk of disease worsening. This pictorial essay illustrates typical and uncommon imaging findings of COVID-19 pneumonia and the role of imaging for patient management.

Malemedicine.medical_specialtyRadiographyPneumonia ViralDiseaseCoronavirus infections030218 nuclear medicine & medical imaging03 medical and health sciencesBetacoronavirus0302 clinical medicinePandemicCoronavirus infectionmedicineHumansRadiology Nuclear Medicine and imagingPandemicsAgedAged 80 and overbusiness.industrySARS-CoV-2Pulmonary embolismOutbreakCOVID-19030208 emergency & critical care medicineMiddle Agedmedicine.diseaseTriagePulmonary embolismCoronavirus disease 2019 (COVID-19)PneumoniaItalyRadiology Nuclear Medicine and imagingEmergency MedicinePictorial EssayFemaleRadiography ThoracicRadiologyPresentation (obstetrics)Settore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessTomography X-Ray ComputedCTEmergency radiology
researchProduct

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: A randomized trial

2009

BACKGROUND: Low-dose oral vitamin K decreases the international normalized ratio (INR) in overanticoagulated patients who receive warfarin therapy. Its effects on bleeding events are uncertain. OBJECTIVE: To see whether low-dose oral vitamin K reduces bleeding events over 90 days in patients with warfarin-associated coagulopathy. DESIGN: Multicenter, randomized, placebo-controlled trial. Randomization was computer-generated, and participants were allocated to trial groups by using sequentially numbered study drug containers. Patients, caregivers, and those who assessed outcomes were blinded to treatment assignment. SETTING: 14 anticoagulant therapy clinics in Canada, the United States, and …

Malemedicine.medical_specialtyRandomizationVitamin Kmedicine.drug_classAdministration OralHemorrhageoral vitamin k anticoagulantsPlacebolaw.inventionSettore MED/15 - Malattie Del SanguePlacebosRandomized controlled trialOral administrationlawInternal medicineThromboembolismInternal MedicinemedicineOutpatient clinicHumansInternational Normalized RatioAgedAged 80 and overbusiness.industryAnticoagulantWarfarinAge FactorsAnticoagulantsGeneral MedicineMiddle AgedAntifibrinolytic AgentsSurgeryClinical trialTreatment OutcomeFemaleWarfarinbusinessmedicine.drug
researchProduct

The predictive value of heart-type fatty acid-binding protein is independent from symptom duration in normotensive patients with pulmonary embolism.

2013

Heart-type fatty acid-binding protein (H-FABP) is a useful biomarker for risk stratification of patients with pulmonary embolism (PE). In patients with acute myocardial infarction, H-FABP plasma concentrations rise after 30 minutes and return to normal within 20-24 hours. We tested whether the predictive value of H-FABP is affected by the duration of symptoms prior to diagnosis in patients with PE.We prospectively studied 257 consecutive normotensive patients with confirmed symptomatic PE.Patients with acute (24 hours; n=150) symptom onset presented more often with syncope (28.7% vs. 6.5%; p0.001) compared to patients with symptoms ≥ 24 hours (n=107); other baseline characteristics, comorbi…

Malemedicine.medical_specialtyRenal function030204 cardiovascular system & hematologyFatty Acid-Binding Proteins03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedbusiness.industryArea under the curveHematologyOdds ratioMiddle Agedmedicine.diseasePrognosisConfidence interval3. Good healthPulmonary embolismHeart-type fatty acid binding proteinCardiologyBiomarker (medicine)lipids (amino acids peptides and proteins)FemalebusinessPulmonary EmbolismFatty Acid Binding Protein 3Thrombosis research
researchProduct

Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke.

2010

Abstract No study has yet evaluated the relationship between arterial stiffness indexes and immuno-inflammatory pathway in patients with an acute cardiovascular or cerebrovascular event. The aim of our study was to evaluate in patients with acute ischemic stroke the relationship between immune-inflammatory markers and arterial stiffness indexes. Methods 107 subjects with acute ischemic stroke and 107 controls without stroke. We evaluated plasma levels of C-reactive protein (CRP), interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10), E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaEmbolismTissue plasminogen activatorVon Willebrand factorIschemiaInternal medicinevon Willebrand FactormedicineHumanscardiovascular diseasesStrokePulse wave velocityAgedAged 80 and overInflammationbiologybusiness.industryCerebral infarctionMiddle Agedmedicine.diseaseAtherosclerosisischemic stroke arterial stiffnessSurgeryStrokeCarotid ArteriesImmune SystemAcute Diseasecardiovascular systemArterial stiffnessCardiologybiology.proteinCytokinesAortic stiffnessFemaleCardiology and Cardiovascular MedicinebusinessPlasminogen activatorcirculatory and respiratory physiologymedicine.drugAtherosclerosis
researchProduct